| Description |
JNJ-3790339, a Ritanserin (HY-10791) analog, is a potent and selective diacylglycerol kinase (DGKα) inhibitor with an IC50 of 9.6 μM. JNJ-3790339 has induction of toxicity in malignant cells, and improves ability to upregulate T cell activation[1].
|
| Related Catalog |
|
| Target |
IC50: 9.6 μM (DGKα)[1]
|
| In Vitro |
JNJ-3790339 (5-40 μM; 48 h) exhibits cytotoxic efficacy against A375, U251 and Jurkat T[1]. JNJ-3790339 (5 μM; 6 h) promotes activation of primary murine T cells[1]. Cell Cytotoxicity Assay[1] Cell Line: A375, U251 and Jurkat T Concentration: 5, 15, 25 and 40 μM Incubation Time: 48 h Result: Exhibited cytotoxic efficacy against cancer cells in a dose-dependent manner. RT-PCR[1] Cell Line: Jurkat T Concentration: 5 μM Incubation Time: 6 h Result: Displayed high activation response with significantly increased CD69 and TNFα expression.
|
